NBIX News Alert Neurocrine Biosciences (NBIX) 20.46 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurocrine Biosciences (NBIX) 20.46 $NBIX

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients
at The Street - Tue Dec 16, 3:06PM CST
Auspex is expected to seek U.S. approval for SD-809 next year.
NBIX: 20.46 (-0.18), ASPX: 25.09 (+0.78)

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 85.87 (-0.33), BIIB: 325.13 (-10.67), ACAD: 30.02 (-0.32), NBIX: 20.46 (-0.18), HALO: 7.64 (-0.03)

Nasdaq stocks posting largest percentage increases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SOFO: 7.69 (+0.25), NBIX: 20.46 (-0.18), DERM: 21.03 (-0.34), CHKE: 19.69 (-0.04), LAYN: 8.67 (+0.50), NDQ.TO: 18.63 (-0.01), CLDN: 17.76 (+0.03), NVDQ: 15.99 (unch), OBAS: 6.96 (-0.06)

Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee
PR Newswire - Thu Dec 11, 8:17AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only. To access our full PDF reports on a complementary basis, please visit the links below.
NBIX: 20.46 (-0.18)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 20.46 (-0.18), TNXP: 6.22 (+0.13), MRNS: 7.90 (-0.28), CPRX: 2.88 (+0.02), VNDA: 12.44 (-0.01), ITCI: 15.75 (+0.08), OMER: 20.51 (-0.62)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 4:39PM CST

RH: 95.09 (+0.09), BXS: 21.36 (+0.03), NBIX: 20.46 (-0.18), BDC: 77.93 (-1.13), GDP: 4.14 (+0.09), APT: 2.52 (-0.07), AUQ: 3.08 (-0.12), LAKE: 9.19 (-0.46), SFUN: 6.84 (-0.66), AGI: 6.48 (-0.47)

Uptrend Call Working As Neurocrine Biosciences Stock Rises 17.7% (NBIX)
Comtex SmarTrend(R) - Wed Dec 10, 10:00AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.65% as of today's recent price of $19.86.
NBIX: 20.46 (-0.18)

Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
PR Newswire - Wed Dec 10, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH, the 1401 Study.
NBIX: 20.46 (-0.18)

Clinovo Presents Its Cloud-Based EDC System ClinCapture at the San Diego Clinical Research Network Event in San Diego
PRWeb - Mon Dec 08, 2:12AM CST
Clinovo presents its cloud-based technology and EDC solution ClinCapture at the San Diego Clinical Research Network event in San Diego on December 9th, 2014. This program provides an introduction to using the cloud in the life sciences and clinical trials.
NBIX: 20.46 (-0.18)

Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Thu Dec 04, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City.
NBIX: 20.46 (-0.18)

17.3% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Wed Dec 03, 9:22AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.30% as of today's recent price of $19.80.
NBIX: 20.46 (-0.18)

Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.
NBIX: 20.46 (-0.18), DB: 30.07 (+0.08)

Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
Business Wire - Wed Nov 19, 7:01AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.
NBIX: 20.46 (-0.18), RTRX: 11.12 (+0.56), AMGN: 159.44 (-0.16)

Neurocrine Biosciences Has Returned 13.2% Since SmarTrend Recommendation (NBIX)
Comtex SmarTrend(R) - Tue Nov 18, 11:13AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 1 month, Neurocrine Biosciences has returned 13.15% as of today's recent price of $19.10.
NBIX: 20.46 (-0.18)

Post Earnings Update: Neurocrine Biosciences Has Climbed 4.2% Higher in Past 2 Weeks (NBIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:01PM CST
When Neurocrine Biosciences (NASDAQ:NBIX) reported earnings two weeks ago on November 3rd, 2014, analysts, on average, expected the company to report a loss of $0.21 on sales of $0.0 thousand. Neurocrine Biosciences actually reported a loss of $0.21 per share on sales of $0.0 thousand, matching EPS estimates and matching revenue estimates. Shares of Neurocrine Biosciences have climbed from $18.15 to $18.92, representing a gain of 4.2% since the company reported earnings 14 days ago.
NBIX: 20.46 (-0.18)

Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed Nov 12, 12:56PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.
NBIX: 20.46 (-0.18)

Neurocrine Biosciences Looking Forward To A Big Year
Stephen Simpson, CFA - at Seeking Alpha - Thu Nov 06, 10:57AM CST

NBIX: 20.46 (-0.18), ABBV: 65.25 (-0.37)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 22

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 39

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 197

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 21

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 194

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 13

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIA Time Launches New College Football Playoff Limited Edition

Updated Category News Views 81

Introducing AXIA Time's New College Football Playoff Collection AXIA Time is making waves with its expanded partnership with the College Football Playoff (CFP) and the launch of a fantastic new collection. Known for its high-quality craftsmanship, AXIA Time has introduced a series of limited edition, heirloom-quality watches specifically created for the 2025 College...

Continue Reading
Uphold Launches Staking Services for UK Users Amid Changes

Updated Category News Views 375

Uphold Introduces Staking Features for UK Customers Customers of Uphold can now take advantage of staking rewards on their crypto assets. This major shift comes after the UK Treasury amended the Financial Services and Markets Act, allowing crypto-asset service providers to offer staking services to individuals and businesses within the United Kingdom. Impact of Regulatory...

Continue Reading
ASDS Annual Conference: Elevating Dermatology Education for 2025

Updated Category News Views 196

Registration Now Open for 2025 ASDS Annual Conference The American Society for Dermatologic Surgery (ASDS) has announced the opening of registration for its highly anticipated annual meeting. This prestigious event gathers dermatologists and their staff for a four-day immersive experience aimed at improving skills and knowledge in dermatologic surgery. The conference will...

Continue Reading
Revolutionizing Order Management with OMS+ Cloud Solution

Updated Category News Views 212

DataXstream Unveils OMS+ Cloud Solution for Enhanced Order Management DataXstream LLC has rolled out its latest innovation, the OMS+ Cloud specifically designed for SAP S/4HANA Cloud Public Edition, aiming to transform how businesses manage their sales and order processes. Transforming Sales and Order Processes For more than a decade, OMS+ has been at the forefront of...

Continue Reading
Innovative Paper Towel Stand Redefines Hygiene and Convenience

Updated Category News Views 170

Revolutionary Design for Paper Towel Dispensing In a world where hygiene is paramount, a visionary inventor from Oakgrove has developed an innovative solution known as the Adjustable Paper Towel Stand. This unique accessory is designed to dispense paper towels one at a time, effectively minimizing contact with the entire roll, which can often lead to contamination and...

Continue Reading